Screener
Haemonetics HAE Blood Management Technologies — Net revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
| Line item | Three Months Ended / June 27, 2026 | June 28, 2025 |
|---|---|---|
| Plasma | $155,524 | $145,074 |
| Other | 35,794 | 36,662 |
| Apheresis net revenues | $191,318 | $181,736 |
| MedSurg | ||
| Interventional Technologies | $59,942 | $58,483 |
| Blood Management Technologies | 88,120 | 81,175 |
| MedSurg net revenues | $148,062 | $139,658 |
| Total net revenues | $339,380 | $321,394 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Haemonetics's blood management technologies — net revenues?
- Haemonetics (HAE) reported blood management technologies — net revenues of $88.12M in Q2 2026.
- What does blood management technologies — net revenues mean?
- This metric represents the total net revenue generated from the sale of products and services within the blood management technologies segment. It captures the financial performance of solutions designed for blood collection, processing, and surgical blood management, reflecting the company's market penetration in hospital and blood center environments. Tracking this revenue stream provides insight into the demand for specialized medical technologies used to improve patient outcomes and operational efficiency in clinical settings.
Ask your AI about Haemonetics's blood management technologies — net revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude